Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: Perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach

Blood Cells, Molecules, and Diseases

Volumn 27, Issue 4, 2001, Pages 757-766

  De Vita, S ^a   De Marchi, G ^a   Sacco, S ^a   Gremese, E ^a   Fabris, M ^a   Ferraccioli, G ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE EXPRESSION; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOSTIMULATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PAROTID GLAND; PRIORITY JOURNAL; RISK FACTOR; SJOEGREN SYNDROME;

EID: 0034749598     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.2001.0446     Document Type: Article

References (53)

1. The development of malignant lymphoma in the course of Sjögren's syndrome
2. Clinical evolution and morbidity and mortality of primary Sjögren's syndrome
3. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome
4. Evidence of lymphoproliferation in the lack of overt lymphoma in Sjögren's syndrome
5. Non malignant lymphoproliferation in Sjögren's syndrome: Proposed classification based on integrated clinicopathologic and molecular studies and follow-up
6. Clonally expanded lymphocytes in the minor salivary glands of Sjögren's syndrome patients without lymphoproliferative disease
7. Analysis of Vh-D-Jh gene transcripts in B cells infiltrating the salivary glands and lymph node tissue of patients with Sjögren's syndrome
8. Oligoclonal non neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia
9. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome
10. Predictors of lymphoma development in primary Sjögren's syndrome
11. Malignant lymphoma in primary Sjögren's syndrome: A multicenter, retrospective clinical study by the European Concerted Action on Sjögren's syndrome
12. Pathologic feature of lymphoid proliferations of salivary glands: Lymphoepithelial sialadenitis vs low-grade B-cell lymphoma of MALT type
13. Primary B-cell lymphoma of salivary gland and its relationship to myoepithelial sialadenitis (MesA)
14. Salivary gland lymphoid infiltrates associated with lymphoepithelial lesion: A clinical, pathologic, immunophenotypic study
15. Lymphoid proliferations of the salivary glands
16. Are there site-specific differences among the MALT lymphomas - Morphologic, clinical?
17. A revised European-American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group
18. Is clonality equivalent to malignancy: Specifically, is immunoglobulin gene rearrangement diagnostic of malignant lymphoma?
19. Uniform detection of immunoglobulin-gene rearrangement in benign lymphoepithelial lesions
20. B cell monoclonality, Epstein - Barr virus and t(14-18) in myoepithelial sialoadenitis and low-grade B cell MALT lymphoma of the parotid gland
21. Regression of primary low-grade B cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
22. Widespread clonal B cell disorder in Sjögren's syndrome predisposing to Helicobacter pylori-related gastric lymphoma
23. B-cell clonality in gastric lymphoid tissue of patients with Sjögren's syndrome
24. Reactive lymphoadenopathies and atypical lymphoproliferative disorders
25. A high incidence of rheumatoid factor idiotype in monoclonal proteins in the patients with Sjögren's syndrome
26. Mixed monoclonal cryo-globulinemia and monoclonal rheumatoid factor cross-reactive idiotype as predictive factors for the development of lymphoma in primary Sjögren's syndrome
27. The inefficacy of corticosteroids in modifying the course of Sjögren's syndrome-associated pseudolymphoma of MALT
28. Local cytokine expression in progression toward B cell malignancy in Sjögren's syndrome
29. Immunoglobulin gene usage and somatic mutations in primary Sjögren's syndrome-associated monoclonal B-cell lymphoproliferation, prelymphomatous and frankly malignant
30. Clonal salivary gland infiltrates associated with lymphoepithelial sialoadenitis (Sjögren's syndrome) begin as nonmalignant antigen-selected expansions
31. B-cell lymphoproliferation in primary Sjögren's syndrome: An antigen driven expansion employing rheumatoid factor-encoding genes
32. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V (H) genes show frequent use of V1-69 with distinctive CDR3 features
33. Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells
34. Salivary gland immunoglobulin and rheumatoid factor synthesis in Sjögren's syndrome. Natural history and response to treatment
35. Molecular characterization of a major autoantibody-associated cross-reactive idiotype in Sjögren's syndrome
36. Sialadenitis histologically resembling Sjögren's syndrome in mice transgenic for hepatitis C virus envelope genes
37. The role of HCV infection in Sjögren's syndrome
38. Sjögren's syndrome and hepatitis C virus
39. Chronic lymphocytic sialoadenitis in HCV-related chronic liver disease: Comparison of Sjögren's syndrome
40. Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma
41. Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia
42. Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis
43. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia
44. The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacements
45. A proposal of modification in the European Classification Criteria for Sjögren's syndrome
46. The biology of low-grade MALT lymphoma
47. Resistance of t(11 ;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy
48. Cytokine expression in the salivary gland of Sjögren's syndrome patients in relation to tissue infiltration and lymphoepithelial lesions
49. Interferon alpha-2 (IFNα2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trials versus OH - Chloroquine
50. Human rheumatoid factor production is dependent on CD40 signaling and autoantigen
51. Remarkable suppression of the Sjögren's syndrome like disease in NZB/W fl mice by blockade of the CD40L-CD40 interaction
52. Haemopoietic stem cell transplantation (HSCT) in a patient with Sjögren's syndrome and lung MALT lymphoma cured lymphoma but not the autoimmune disease